Summary
121.83 0.76(0.62%)05/08/2024
Moderna Inc (MRNA)
Moderna Inc (MRNA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.81 | 9.73 | 15.29 | 21.87 | 64.42 | -8.08 | 393.32 | 551.13 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 121.11 | |
| Open | 122.86 | |
| High | 123.49 | |
| Low | 118.68 | |
| Volume | 2,434,992 | |
| Change | -0.99 | |
| Change % | -0.81 | |
| Avg Volume (20 Days) | 3,023,371 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 62.65 - 142.79 | |
| Price vs 52 Week High | -15.18% | |
| Price vs 52 Week Low | 93.31% | |
| Range | -1.42 | |
| Gap Up/Down | -2.29 | |
Fundamentals | ||
| Market Capitalization (Mln) | 46,713 | |
| EBIDTA | 7,772,106,752 | |
| PE Ratio | 16.6044 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 301.20 | |
| Book Value | 24.9980 | |
| Earnings Per Share | 16.6920 | |
| EPS Estimate Current Quarter | 9.0500 | |
| EPS Estimate Next Quarter | 10.9700 | |
| EPS Estimate Current Year | 25.8900 | |
| EPS Estimate Next Year | 26.5800 | |
| Diluted EPS (TTM) | 16.6920 | |
| Revenues | ||
| Profit Marging | 0.5968 | |
| Operating Marging (TTM) | 0.6433 | |
| Return on asset (TTM) | 0.3720 | |
| Return on equity (TTM) | 1.0961 | |
| Revenue TTM | 11,831,395,328 | |
| Revenue per share TTM | 29.5170 | |
| Quarterly Revenue Growth (YOY) | 30.6500 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -574,877,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 16.6044 | |
| Forward PE | 10.6270 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 10.2948 | |
| Revenue Enterprise Value | 8.1057 | |
| EBITDA Enterprise Value | 12.3257 | |
| Shares | ||
| Shares Outstanding | 405,449,984 | |
| Shares Float | 367,385,925 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 9.51 | |
| Institutions (%) | 61.15 | |
05/08 12:02 EST - Investors Business Daily
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?
Is Moderna Stock A Buy On Its Eye-Popping First-Quarter Sales Beat?
Moderna stock broke out of a cup-with-handle base after its first-quarter sales and earnings report. Is MRNA stock a buy right now?
05/05 03:00 EST - Barrons
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
Largest U.S. Pension Sold Verizon, Disney, and Peloton Stock. It Bought Moderna.
Calpers slashed investments in Verizon, Disney, and Peloton stock, and doubled down on Moderna shares in the first quarter.
05/03 06:15 EST - InvestorPlace
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street's Radar
Pharma stocks and massive potential go hand in hand. With devastating diseases like cancer, diabetes and heart disease still far from finding a cure, drugs that treat these conditions often command exorbitant prices.
05/02 18:36 EST - The Motley Fool
Why Moderna Stock Blasted 13% Higher Today
Investors and analysts broadly expected the biotech's results to wither in the first quarter, and they were right. Still, it did better than many anticipated.
Why Moderna Stock Blasted 13% Higher Today
Investors and analysts broadly expected the biotech's results to wither in the first quarter, and they were right. Still, it did better than many anticipated.
05/02 16:31 EST - Schwab Network
Moderna (MRNA) CFO on Earnings & Outlook
Moderna's (MRNA) adjusted EPS came in at -$3.07 versus an estimated -$3.59 and revenue came in at $167.00M versus an estimated $124.74M. CFO Jamey Mock joins Oliver Renick to discuss Moderna's 1Q earnings and the outlook for the company.
Moderna (MRNA) CFO on Earnings & Outlook
Moderna's (MRNA) adjusted EPS came in at -$3.07 versus an estimated -$3.59 and revenue came in at $167.00M versus an estimated $124.74M. CFO Jamey Mock joins Oliver Renick to discuss Moderna's 1Q earnings and the outlook for the company.
05/02 13:48 EST - Yahoo Finance
Moderna CEO talks Q1 earnings, Brazil COVID vaccine, and cancer treatment markets
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market.
Moderna CEO talks Q1 earnings, Brazil COVID vaccine, and cancer treatment markets
Shares of pharmaceutical company Moderna (MRNA) are on the rise despite first quarter losses. Moderna CEO Stéphane Bancel tells Yahoo Finance Senior Reporter Anjalee Khemlani that the company is busy developing updated coronavirus vaccines for the 2024-2025 season and recently announced an expansion into the Brazilian market.
05/02 12:16 EST - Zacks Investment Research
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
Moderna (MRNA) Q1 Earnings Beat Estimates, Revenues Down Y/Y
Moderna (MRNA) beats expectations for both earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.
05/02 10:18 EST - Stockmarketcom
2 Biotech Stocks To Watch Today Amid Earnings
Here are two biotech stocks to watch after their recent earnings report.
2 Biotech Stocks To Watch Today Amid Earnings
Here are two biotech stocks to watch after their recent earnings report.
05/02 08:40 EST - Zacks Investment Research
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago.
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Moderna (MRNA) came out with a quarterly loss of $3.07 per share versus the Zacks Consensus Estimate of a loss of $3.59. This compares to earnings of $0.19 per share a year ago.
05/02 08:15 EST - CNBC Television
Moderna CEO Stephane Bancel on Q1 results: The vaccine platform is coming together very nicely
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, which posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine topped estimates, vaccine pipeline, growth outlook, and more.
Moderna CEO Stephane Bancel on Q1 results: The vaccine platform is coming together very nicely
Moderna CEO Stephane Bancel joins 'Squawk Box' to discuss the company's quarterly earnings results, which posted a narrower-than-expected loss for the first quarter as the company's cost-cutting efforts took hold and sales of its Covid vaccine topped estimates, vaccine pipeline, growth outlook, and more.
05/02 07:00 EST - Invezz
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch
Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year. Moderna beats loss estimates, revenue expectations In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch
Moderna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year, setting a positive tone as it prepares to launch its second product in the U.S. market later this year. Moderna beats loss estimates, revenue expectations In the first quarter, Moderna recorded a net loss of $1.175 billion, or $3.
05/02 06:48 EST - Market Watch
Highly ranked manager who bet on Mag 7 giants looks to these second-order winners from AI
Large-cap growth funds have been in the sweet spot for a few years now, thanks to megacap tech holdings.
Highly ranked manager who bet on Mag 7 giants looks to these second-order winners from AI
Large-cap growth funds have been in the sweet spot for a few years now, thanks to megacap tech holdings.
05/02 06:35 EST - CNBC
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
Moderna loses less than expected as Covid vaccine sales beat estimates, cost cuts take hold
The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.
05/02 06:33 EST - Reuters
Moderna quarterly sales beat expectations but plummet from previous year
Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.
Moderna quarterly sales beat expectations but plummet from previous year
Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.
05/02 06:33 EST - Market Watch
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Moderna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks to launch its second product in the U.S. later this year.
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Moderna Inc. on Thursday reported a narrower-than-expected first-quarter loss as the COVID vaccine maker looks to launch its second product in the U.S. later this year.
05/02 06:00 EST - InvestorPlace
Stock Market Crash Warning: Don't Get Caught Holding These 3 Cathie Wood Stocks
For a time, Cathie Wood was the hottest investor on Wall Street. Ark Invest was bringing in billions of dollars in new assets under management.
Stock Market Crash Warning: Don't Get Caught Holding These 3 Cathie Wood Stocks
For a time, Cathie Wood was the hottest investor on Wall Street. Ark Invest was bringing in billions of dollars in new assets under management.
05/01 14:38 EST - InvestorPlace
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.
Shhh! 3 Secret Biotech Stocks Flying Below Wall Street's Radar
Biotech stocks are full of intriguing innovators who could help pave the way for greater gains over the years ahead. Undoubtedly, it's virtually impossible to tell exactly which pills, shots and treatments within a firm's pipeline will eventually evolve into cash flows, let alone blockbuster cash cows.
05/01 12:11 EST - Zacks Investment Research
Why Earnings Season Could Be Great for Moderna (MRNA)
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Earnings Season Could Be Great for Moderna (MRNA)
Moderna (MRNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
04/30 15:20 EST - InvestorPlace
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
3 Biotech Stocks with Blockbuster Drug Pipelines: April Edition
Biotech stocks offer the opportunity to invest in life-saving treatments and drugs. So not only can you make massive gains but you are also investing in the advancement of modern medicine.
04/30 12:21 EST - Zacks Investment Research
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.
Will These 5 Drug/Biotech Stocks Beat Q1 Earnings Forecast?
Let's look at five large-cap pharma/biotech companies slated to release quarterly results this week.